ToxLens is a reproducible multi‑task graph‑learning framework designed for leakage‑aware, uncertainty‑calibrated prediction of 11 molecular toxicity endpoints, including Ames mutagenicity and hERG inhibition. The workflow integrates conservative chemical curation, sphere‑exclusion filtering, a leakage‑aware UMAP‑HDBSCAN split, parallel graph and global‑feature encoders with late concatenation, temperature‑scaled Monte Carlo dropout, conformal‑style prediction sets, applicability‑domain analysis, and SHAP‑guided toxicophore discovery with occlusion controls. On a leakage‑controlled test fold, a five‑seed soft‑voting ensemble achieved MCC 0.44, AUROC 0.83, and AUPRC 0.58, outperforming four ECFP4‑based shallow baselines across all endpoints.
arXiv:2609.37555v1 Announce Type: new Abstract: Drug discovery is a costly and high-risk process, where toxicity-related failures remain a major cause of attrition in both preclinical and clinical st...
HierDTA is a hierarchical structure‑aware framework for drug–target affinity prediction that represents drugs as atom–motif heterogeneous graphs and proteins as residue interaction graphs. It integrates atom and residue representations via cross‑attention, supplemented by molecule fingerprints and pretrained ESM‑2 embeddings, achieving superior performance on the Davis and KIBA datasets and strong generalization in cold‑start scenarios. Ablation studies and interpretability analyses confirm the contributions of its hierarchical augmentation and interaction components, and case studies demonstrate early enrichment of candidate bioactive compounds.
SMILESGNN is a multimodal architecture that fuses a SMILES Transformer encoder with a GATv2 graph encoder through cross‑attention, enabling interpretable clinical toxicity predictions. The model retains an explicit graph branch, allowing GNNExplainer to identify substructures linked to toxicity. On the ClinTox dataset it achieves an AUC‑ROC of 0.987 and F1 of 0.906 with only 0.4 M parameters, while on Tox21 it attains a mean AUC‑ROC of 0.750, comparable to strong single‑modality baselines.
arXiv:2606. 07698v1 Announce Type: cross Abstract: Graph neural networks (GNNs) applied to drug-drug interaction (DDI) prediction rely exclusively on molecular structure encoded as SMILES-derived graphs.
arXiv:2607. 24314v1 Announce Type: new Abstract: Predicting the absorption, distribution, metabolism, excretion and toxicity (ADMET) properties of small molecules remains a major challenge in drug discovery.
arXiv:2609.37384v1 Announce Type: new Abstract: Molecular representation learning is central to computer-aided drug discovery. Molecular graphs, SMILES strings, and 3D conformations provide complemen...
arXiv:2506. 10912v4 Announce Type: replace Abstract: Toxicity remains a leading cause of early-stage drug development failure.
arXiv:2608. 04257v1 Announce Type: new Abstract: Blood-brain barrier permeability (BBBP) prediction is a critical screening task in central nervous system drug discovery, where candidate molecules must be assessed for whether they can cross, or should be prevented from crossing, the blood-brain barrier.
arXiv:2606. 04021v1 Announce Type: cross Abstract: Proteolysis-targeting chimeras (PROTACs) can selectively degrade disease-causing proteins, yet predicting which targets are amenable to degradation remains a critical bottleneck: existing computational methods require the complete PROTAC molecular structure, information unavailable before synthesis.
Monroe is a new molecular foundation model that improves upon existing models by pre‑training on over 81 million molecules from the PM6 quantum chemistry dataset, enhancing stereochemistry representation, and introducing novel training losses such as conformer denoising and embedding decorrelation. It also incorporates a prior‑data‑fitted model (TabPFN) for downstream in‑context prediction and demonstrates superior performance on Polaris benchmarks and activity cliff tests. Ablation studies show that the PFN‑based downstream approach can upgrade other models, producing state‑of‑the‑art variants MiniMol_PFN and CheMeleon_PFN.
arXiv:2606. 04020v1 Announce Type: cross Abstract: Splice-mediated drug resistance occurs in up to 40% of patients on targeted kinase inhibitors, yet state-of-the-art druggability tools operate on single structures and cannot compare across isoforms.
The paper introduces D2ML, a set of machine‑learning models designed for Direct‑to‑Biology (D2B) small‑molecule screening. These assay‑aware models predict activity from single‑point screens, relative potency across targets from crude dose‑response assays, and absolute potency from purified‑compound measurements, and a joint model that shares information across stages improves predictions, especially for crude dose‑response selectivity. Using these models, the authors guided the synthesis of 84 new compounds that extended the Pareto front of potency and selectivity, achieving a ROS1 IC₅₀ of 14.7 nM with 233‑fold selectivity over TRKB, surpassing the best training compound.